In this podcast, the first in our Rare Conversations series, our CEO Simon Estcourt explains why this is an exciting time to be involved in rare disease research.
Thanks to an increased awareness of the challenges faced by the rare disease population, greater support for the biotech/pharma industry in developing effective treatments and the growth of patient advocacy groups, he sees a future full of opportunity and hope for people living with a rare disease. Equally, the implementation of more hybrid approaches is making clinical trials significantly more accessible for patients, whilst advances in technology (such as AI) are bringing a new level of flexibility to protocol design.
Watch the full podcast to find out why Simon believes these developments are improving clinical studies to deliver life-changing treatments to patients faster and more effectively.